Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta Therapeutics Inc.

www.melinta.com

Latest From Melinta Therapeutics Inc.

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Complete Response Letters Regulation

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?

The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.

Complete Response Letters Drug Safety

Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela

In all-stock transaction, troubled Cempra will merge with privately held Melinta to create a fully integrated anti-infectives company.

M & A Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Rib-X Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Melinta Therapeutics Inc.
  • Senior Management
  • Eugene Sun, MD, CEO
    Paul Estrem, CFO
    Sue Cammarata, MD, CMO
    Lyn Baranowski, SVP, Corp. Dev. & Strategy
    Erin Duffy, PhD, CSO
    John Temperato, Pres. & COO
  • Contact Info
  • Melinta Therapeutics Inc.
    Phone: (203) 624-5606
    300 George St., Ste. 301
    New Haven, CT 06511-6663
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register